Technical Analysis for LADX - Ladrx Corp
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | N/A | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Buy Signal | Bullish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Bullish Engulfing | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | 11.11% | |
NR7-2 | Range Contraction | 11.11% | |
Narrow Range Bar | Range Contraction | 11.11% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Biopharmaceutical Chemotherapy Cancer Treatments Antineoplastic Drugs Doxorubicin Aldoxorubicin Cytrx
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Biopharmaceutical Chemotherapy Cancer Treatments Antineoplastic Drugs Doxorubicin Aldoxorubicin Cytrx
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Date | Title |
---|---|
Nov 17 | LadRx Corporation Issues Corporate Update for 3Q22 |
Indicator | Value |
---|---|
52 Week High | 0.22 |
52 Week Low | 0.051 |
Average Volume | 103,220 |
200-Day Moving Average | 0.0000 |
50-Day Moving Average | 0.1510 |
20-Day Moving Average | 0.1172 |
10-Day Moving Average | 0.1130 |
Average True Range | 0.0264 |
RSI | 41.18 |
ADX | 13.9 |
+DI | 16.2243 |
-DI | 19.3933 |
Chandelier Exit (Long, 3 ATRs) | 0.0908 |
Chandelier Exit (Short, 3 ATRs) | 0.1302 |
Upper Bollinger Bands | 0.1564 |
Lower Bollinger Band | 0.0780 |
Percent B (%b) | 0.28 |
BandWidth | 66.8942 |
MACD Line | -0.0141 |
MACD Signal Line | -0.0122 |
MACD Histogram | -0.0019 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.1150 | ||||
Resistance 3 (R3) | 0.1167 | 0.1133 | 0.1125 | ||
Resistance 2 (R2) | 0.1133 | 0.1095 | 0.1125 | 0.1117 | |
Resistance 1 (R1) | 0.1067 | 0.1072 | 0.1050 | 0.1050 | 0.1108 |
Pivot Point | 0.1033 | 0.1033 | 0.1025 | 0.1025 | 0.1033 |
Support 1 (S1) | 0.0967 | 0.0995 | 0.0950 | 0.0950 | 0.0892 |
Support 2 (S2) | 0.0933 | 0.0972 | 0.0925 | 0.0883 | |
Support 3 (S3) | 0.0867 | 0.0933 | 0.0875 | ||
Support 4 (S4) | 0.0850 |